First-Ever Treatment for Ultra-Rare Rapid-Aging Disease Progeria Receives Approval in Japan streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ The Progeria Research Foundation (PRF) today announced a new milestone with the approval of Zokinvyâ„¢ (lonafarnib) by the Japanese Ministry of.
First-Ever Treatment for Ultra-Rare Rapid-Aging Disease Progeria Receives Approval in Japan streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Clinical trial data demonstrated Zokinvy treatment extended life by an average of 4.3 years in children and young adults with Hutchinson-Gilford progeriaEiger to receive $500,000 approval milestone.